Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer
Printer Friendly Page TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

Clinicaltrials.gov identifier:
NCT02975934

Treatment

Study Contact Information:

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.


A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

About the Study

The purpose of Triton3 is to determine how patients with castration-resistant cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the rucaparib () compared to treatment with physician's choice of acetate, , or docetaxel.  NOTE: This study is no longer enrolling patients.

 

Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email  

This Study is Open To:

NOTE: This study is no longer enrolling patients.

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.